SEC Filing Summary
Identity note: The supplied filing is Rexahn Pharmaceuticals, Inc.’s Form 10-Q for the quarter ended September 30, 2013—not an Opus Genetics filing. The summary below reflects the filing text provided.
Business context and reporting period
Rexahn described itself as a development-stage biopharmaceutical company focused on cancer treatments. It had no commercial sales revenue and reported results for the three and nine months ended September 30, 2013, compared with the same periods in 2012. The financial statements are unaudited.
Financial performance and liquidity
| Metric | 2013 | Comparable 2012 |
|---|---|---|
| Revenue, three and nine months | $0 | $0 |
| Operating expenses, three months | $1.824 million | $1.800 million |
| Operating expenses, nine months | $5.646 million | $5.533 million |
| Net loss, three months | $2.141 million | $2.989 million |
| Net loss, nine months | $6.780 million | $6.171 million |
| Basic and diluted loss per share, three months | $0.02 | $0.03 |
| Basic and diluted loss per share, nine months | $0.06 | $0.06 |
| Cash used in operations, nine months | $5.736 million | $5.546 million |
At September 30, 2013, cash and cash equivalents were $14.871 million, marketable securities were $0.100 million, and restricted cash was $0.509 million. The company reported total assets of $16.074 million, total liabilities of $6.222 million, and stockholders’ equity of $9.851 million. Current assets were $15.494 million and current liabilities were approximately $6.222 million. No outstanding borrowing balance is shown on the balance sheet.
Net cash increased $1.384 million in the first nine months, mainly reflecting $6.584 million of financing cash inflows, including proceeds from the July equity offering and warrant and option exercises. No meaningful revenue-based margin is available because revenue was zero.
Material changes versus the prior comparable period
- Third-quarter net loss narrowed from $2.989 million to $2.141 million, while nine-month net loss increased from $6.171 million to $6.780 million.
- Third-quarter general and administrative expense rose 55.4% to $0.933 million, attributed principally to investor-relations and advisory services, stock compensation, and legal and professional costs.
- Research and development expense declined 26.7% for the quarter and 27.7% for the nine-month period. RX-3117 costs funded through Teva’s deferred research arrangement were not recorded as company R&D expense in 2013.
- Noncash warrant remeasurement produced a $1.056 million loss for the nine-month period, versus a $0.656 million loss in 2012. Warrant liabilities increased to $4.192 million from $2.842 million at year-end 2012.
Outlook, developments, and risks
Management estimated that available cash, restricted cash, and marketable securities would cover approximately 24 months of minimum planned operating needs, assuming the company focused resources on selected programs. The company expected to require additional capital to continue development; if financing were unavailable or inadequate, it said it might reduce R&D, beginning with preclinical programs. Management’s stated runway assessment included subsequent-event financing.
- Pipeline: Supinoxin (RX-5902) entered a Phase I trial during the quarter. The company anticipated starting Phase I development of RX-3117 and a Phase IIa renal-cell-carcinoma study of Archexin in the fourth quarter of 2013. These were expectations, not reported completions.
- Teva: Teva declined to exercise its RX-3117 license option, and the research and exclusive license option agreement was terminated. Rexahn retained global rights; $471,679 of remaining restricted funds was to be applied to unbilled costs or returned to Teva. The filing identifies the loss of Teva support as a risk to Rexahn’s ability to fund RX-3117.
- Financing and dilution: The July 2013 offering raised $5.7 million gross through common stock and warrants. After quarter-end, an October offering raised $5.3 million gross; warrant exercises in October generated a further $0.889 million, with 1.883 million shares issued. These transactions increased cash but also involved share issuance and warrants.
- Program costs and execution: Management estimated study costs of approximately $4.0 million for Archexin’s planned renal-cell-carcinoma study, $1.8 million for RX-3117 Phase I, and $2.1 million for Supinoxin Phase I. It noted that trial timing and costs are uncertain and dependent on third parties, regulatory processes, and clinical outcomes.
- Other obligations: The office lease was extended through June 2019; disclosed future rent payments totaled $0.891 million. A $1.0 million KRICT milestone payment would be due upon specified marketing approval, which had not occurred.
- Controls and legal matters: Management concluded disclosure controls were effective at quarter-end and reported no material change in internal control over financial reporting. The filing reported no legal proceedings.
Important facts for investors to verify
- Confirm the issuer: the supplied document identifies Rexahn Pharmaceuticals, Inc., despite the request metadata naming Opus Genetics, Inc.
- Check subsequent filings for actual spending, financing proceeds, cash runway, and whether the stated 24-month operating estimate remained valid.
- Track clinical-trial starts, enrollment, results, regulatory status, and actual development costs for Archexin, RX-3117, and Supinoxin.
- Review the accounting and potential dilution associated with the $4.192 million warrant liability and outstanding warrants and options.
- Clarify the research-and-development contract commitment disclosure: the filing states estimated contract costs of approximately $21.511 million and payments since inception of approximately $19.483 million, but does not clearly explain the resulting remaining commitment.